Two years ago, I took a single 20 mg dose of escitalopram. Like millions of others, I was prescribed this antidepressant with the expectation that it would help, or at worst, have mild side effects that would pass. Instead, I experienced an immediate and severe adverse reaction. What I could not have imagined then was that the symptoms would not resolve; they have persisted and, over time, have only worsened.

Since that day, my life has been profoundly altered. I now live with a constellation of persistent neurological and physical symptoms, including:

• Severe fatigue and profound lack of energy
• Sleep disturbance (inability to nap, waking unrefreshed and sick)
• Temperature dysregulation (fluctuating between feeling chilled and overheated)
• Abnormal breathing sensations
• Chronic nausea, reduced appetite, and unintentional weight loss
• Muscle twitching, joint pain, and unusual body sensations
• Loss of libido and sexual dysfunction
• Cognitive dysfunction (memory lapses, poor concentration, and slowed thinking)
• A constant, “agony-like” inner brain state that is difficult to describe but unrelenting

Despite consulting multiple physicians and specialists, I have not been given a clear explanation or treatment plan. Most often, my concerns are dismissed with some version of: “SSRIs don’t cause long-term effects from a single dose.” Yet my lived experience (and the growing reports of others with similar outcomes) suggests that this assumption may not be true for everyone.

The diagnostic blind spot

One of the greatest challenges is that there is no diagnostic framework for patients like me. When symptoms persist beyond the expected timeframe for drug metabolism or discontinuation, we fall into a grey zone. There are advanced research tools, such as PET imaging of serotonin receptors and transporters, that could provide objective insights into receptor availability, transporter binding, or other neurochemical changes. However, these tools are rarely available in clinical practice.

Without such tools, patients remain in limbo. Our symptoms are real and disabling, yet we are often left without validation, without a diagnosis, and without a treatment pathway.

The human toll

The impact on my daily life has been profound. My ability to work, maintain relationships, and engage in basic activities has been compromised. The chronic fatigue and dysregulated body functions make even simple routines overwhelming. Perhaps most difficult is the invisibility of the condition: because the symptoms are internal and poorly understood, there is little recognition from the medical system.

I know I am not alone. In online communities and patient reports, there are others who describe persistent adverse effects after SSRIs (sometimes after discontinuation, sometimes even after brief exposure). While the terminology varies (e.g., post-SSRI syndrome, persistent adverse reaction), the underlying issue is consistent: Some patients do not return to baseline after exposure to these medications.

Why this matters for psychiatry

I share my story not to discourage the use of SSRIs, which help many people, but to highlight a critical gap in psychiatric care and research. If even a small subset of patients are vulnerable to lasting serotonergic dysfunction, this must be acknowledged and studied.

Psychiatrists should be aware of this possibility, so that when a patient presents with severe and persistent symptoms following SSRI initiation, they are not simply dismissed. Instead, these cases should be recognized as opportunities to investigate receptor signaling, transporter function, and other neurobiological mechanisms that may underlie persistent adverse states.

At a clinical level, this means listening to patients, documenting these experiences, and considering collaborations with neurologists, neuroimaging experts, and pharmacologists to explore diagnostic tools. At a research level, it means prioritizing studies that examine why some patients experience enduring effects while others do not.

A call for awareness and research

As a patient, my greatest hope is twofold:

• To find a path toward recovery.
• To ensure that others who experience persistent SSRI reactions are recognized, believed, and studied.

I urge the psychiatric community to look more closely at these cases, not as anomalies to dismiss, but as important signals about the complexity of serotonergic systems and the need for precision in psychopharmacology.

For those of us living with these symptoms, acknowledgment is the first step toward healing. For psychiatry as a field, it may be the first step toward preventing future suffering and developing better treatments.

Scott McLean is a patient advocate.